{"entity":{"id":"nct07052214","kind":"trial","name":"PSMA PET Combined With MRI for the Detection of PCa","aka":[],"tldr":"A phase 3 trial of Gallium-68 gozetotide in prostate cancer, run by Telix Pharmaceuticals (Innovations) Pty Limited, now recruiting.","summary":"PSMA PET Combined With MRI for the Detection of PCa is a phase 3 interventional study registered as NCT07052214 by Telix Pharmaceuticals (Innovations) Pty Limited, with 338 participants planned, started 2025-08-18 and due to reach its primary completion in 2027-01. Interventions recorded: 68Ga-PSMA-11. Conditions listed: PCA, Prostate Cancer, Prostatic Neoplasm, PSMA PET. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07052214","url":"https://clinicaltrials.gov/study/NCT07052214"}],"tags":["ctgov-ingest"],"related":[],"cancers":["prostate"],"sections":[],"technologies":[],"targets":[],"drugs":["ga68-psma-11"],"companies":["telix"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07052214","phase":"3","setting":"A Single Arm, Multicenter, Prospective, Open Label, Longitudinal Phase 3 Study of Prostate Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) Combined With Magnetic Resonance Imaging (MRI) Compared to Standard of Care (SOC) for the Detection of Prostate Cancer (PCa).","sponsor":"Telix Pharmaceuticals (Innovations) Pty Limited","enrolled":338,"outcomes":[]},"route":"/trials/nct07052214/","neighbours":{"cancer":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"drug":[{"id":"ga68-psma-11","kind":"drug","name":"Gallium-68 gozetotide (PSMA-11)","route":"/drugs/ga68-psma-11/"}],"company":[{"id":"telix","kind":"company","name":"Telix Pharmaceuticals","route":"/companies/telix/"}]}}